Skip to content
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Evolving Psychedelic Paradigm
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
JCP Podcast
Rounds in the General Hospital
View All
Douglas L. Boggs, PharmD
PCC
Letter to the Editor
Substance Use and Cannabis Withdrawal
September 1, 2016
Cannabis withdrawal symptoms are clinically significant because they may act as negative reinforcement for relapse to cannabis use. Here, the authors present data on psychoactive substance use before and...
Deanna L. Kelly
,
Robert P. McMahon
,
Fang Liu
, et al
PCC
Letter to the Editor
Treatment of Hyperprolactinemia and Gynecomastia With Adjunctive Aripiprazole in 2 Men Receiving Long-Acting Injectable Antipsychotics
July 18, 2013
Deepak C. D' Souza
,
Mohini Ranganathan
,
Douglas L. Boggs
, et al
JCP
Original Research
A Randomized Double-Blind Trial of Atomoxetine for Cognitive Impairments in 32 People With Schizophrenia
April 7, 2009
Dwight Dickinson
,
Robert R. Conley
,
Robert W. Buchanan
, et al
